Today: 7 February 2026
Subscribe
Browse Category

Health News News 12 August 2025 - 20 August 2025

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Major Corporate & Industry Announcements Clinical Trials & Drug Regulatory Updates Scientific & Medical Research Breakthroughs (Note: The above research highlights were reported in peer-reviewed journals and scientific news outlets around this time, underlining the broader scientific context during the news cycle.) Public Health & Policy Highlights Sources: Key information in this report is drawn from reputable industry and news outlets including Reuters reuters.com reuters.com, Fierce Biotech/Pharma fiercebiotech.com fiercebiotech.com, Endpoints News, STAT, and official statements from organizations like the FDA, EMA, WHO, and leading medical journals. For full details and additional context, please refer to the cited sources inline.
20 August 2025
··
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy (semaglutide) received FDA accelerated approval to treat metabolic dysfunction-associated steatohepatitis (MASH), becoming the first GLP-1 therapy cleared for MASH in a patient population estimated at about 5% of U.S. adults, based on part 1 of an ongoing trial showing liver health improvement. Tonix Pharmaceuticals’ Tonmya, or TNX-102 SL, was approved August 15 for fibromyalgia, the first new fibromyalgia therapy in 15 years, with two Phase 3 trials showing significantly reduced daily pain versus placebo at 14 weeks and a potential peak U.S. sales of about $800 million. Pfizer’s inclacumab, a P-selectin inhibitor acquired via the 2022 $5.4 billion Global
16 August 2025
···
Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

IO Biotech’s Phase 3 melanoma vaccine Cylembia added to Merck’s Keytruda narrowly missed statistical significance, with median progression-free survival of 19.4 months versus 11 months for Keytruda alone. Fosun Pharma’s deal with Expedition Therapeutics grants rights outside Greater China to XH-S004, a first-in-class oral DPP-1 inhibitor for chronic respiratory diseases, in a pact potentially worth up to $645 million including $120 million upfront and up to $525 million in milestones. NextRNA Therapeutics announced on August 11 it is winding down operations after cash constraints, leaving about 27 employees. FDA approved ketamine (brand name KETARx) from PharmaTher Holdings for surgical anesthesia
12 August 2025
1 2 3

Stock Market Today

Netflix stock price ends higher as DOJ widens review of Warner deal — what to watch next week

Netflix stock price ends higher as DOJ widens review of Warner deal — what to watch next week

7 February 2026
Netflix shares rose 1.6% to $82.20 Friday as the Justice Department expanded its antitrust review of the company’s planned $82.7 billion Warner Bros Discovery acquisition. A Wall Street Journal report said investigators are probing possible anti-competitive tactics. Director Reed Hastings reported a transfer of 241,944 shares via a family trust, according to an SEC filing.
Go toTop